Market participants are watching FDA feedback on new delivery systems, which could shift valuation models. Options activity shows increased put volume this week, signaling some hedging against biotech volatility. MACD indicators are approaching a bullish crossover level. We can see that insiders own shares in MannKind Corporation. It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, they own around US$29m worth of shares (at current prices). If you would like to explore the question of insider alignment, you can click here to see if insiders have been buying or selling. We have seen 95 institutional investors add shares of $MNKD stock to their portfolio, and 143 decrease their positions in their most recent quarter. MNKD stock price forecast is influenced by biotech sector trends, which have shown mixed performance in early
